Sareum Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAR.L research report →
Companywww.sareum.com
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase.
- CEO
- Stephen Barry Parker DPhil
- IPO
- 2004
- Employees
- 5
- HQ
- Cambridge, GB
Price Chart
Valuation
- Market Cap
- $29.45M
- P/E
- -5.94
- P/S
- 0.00
- P/B
- 24.51
- EV/EBITDA
- -4.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -284.01%
- ROIC
- -293.31%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,438,000 · -29.77%
- EPS
- $-0.04 · 14.22%
- Op Income
- $-3,380,000
- FCF YoY
- 34.91%
Performance & Tape
- 52W High
- $29.00
- 52W Low
- $9.50
- 50D MA
- $18.43
- 200D MA
- $18.03
- Beta
- -0.81
- Avg Volume
- 206.64K
Get TickerSpark's AI analysis on SAR.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SAR.L Coverage
We haven't published any research on SAR.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SAR.L Report →